From discovery to therapeutics to patients

Akston Biosciences Corporation aims to be the world’s most efficient model for developing cost-effective, high impact biologic pharmaceuticals to address our most critical healthcare needs. We are built to bring innovative new biologics through the riskiest development phases faster, more cost-effectively, and with a higher likelihood of success.

A Versatile Platform

Akston’s Ambifect technology gives us the versatility to create new biologics and to efficiently bring our therapeutics to the patients who need them most. Our platform cuts the cost, time, and risk of developing new products by using a manufacturing platform that is well-known by the regulators, inherently scalable, and high yielding.

Our Own Manufacturing Infrastructure

Akston is vertically integrated from discovery through GMP manufacturing through deep involvement in clinical trials. We own and operate a GMP biologics factory to support the clinical and commercial development of Akston’s therapeutics. We manage quality control and cost by owning the key manufacturing infrastructure.

Deep Partnerships

Akston is building deep partnerships around the world. We license our patents for commercialization and maintain close involvement with our partners in the development process. We are focused on the entire process – from discovery to therapeutics to patients.


Akston’s approach speeds the time to profit, resulting in innovative, affordable and globally accessible drug therapies for today’s most vexing healthcare issues with significant potential to transform the industry.



Ambifect™ platform for all candidates


A strong and durable pipeline